Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
about
Genomic profiling in luminal breast cancerUtility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus StatementAssociation between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer.Trends in post-mastectomy reconstruction: a SEER database analysis.Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients.Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsGenomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.The 21-gene recurrence score complements IBTR! Estimates in early-stage, hormone receptor-positive, HER2-normal, lymph node-negative breast cancer.Why does Oncotype DX recurrence score reduce adjuvant chemotherapy use?Toward individualized breast cancer therapy: translating biological concepts to the bedside.Low Concordance between Gene Expression Signatures in ER Positive HER2 Negative Breast Carcinoma Could Impair Their Clinical Application.Patient-specific meta-analysis for risk assessment using multivariate proportional hazards regressionIntegrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes.The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay.Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis.A Validated Model for Identifying Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay.Adoption of Gene Expression Profiling for Breast Cancer in US Oncology Practice for Women Younger Than 65 Years.Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013Synchronous invasive ductal carcinoma in encapsulated papillary ductal carcinoma.Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors.The impact of the Oncotype DX Recurrence Score on treatment decisions and clinical outcomes in patients with early breast cancer: the Maccabi Healthcare Services experience with a unified testing policyComparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersHigh-risk estrogen-receptor-positive breast cancer: identification and implications for therapy.Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?The Role of the 21-Gene Recurrence Score in Breast Cancer Treatment.Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancerInternet tools to enhance breast cancer care.The feasibility of a randomised controlled trial for the axillary management of a select group of invasive breast cancer patients: SLNB vs. no-SLNB.Has discovery-based cancer research been a bust?Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer.Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer?Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.Spotlight on the utility of the Oncotype DX® breast cancer assay.[Molecular pathology for breast cancer: Importance of the gene expression profile].[Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67].A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score.Development and validation of a new predictive model for breast cancer survival in New Zealand and comparison to the Nottingham prognostic index
P2860
Q26862681-3ED5BF27-3533-4016-9917-7D42F32A22D7Q27020973-667C715A-311B-43D4-A826-C1DBB6CBDC68Q30378787-94FA21ED-DCB0-4EBE-9CDF-DD100D0CAD77Q33668941-EC73A315-58C0-46D8-8882-0C675B07851AQ33888929-0CB5E554-0A24-4EFD-8419-36E196FF51E0Q35008290-17179398-07FC-470E-ACA4-AACC77821754Q35021646-E52BEBE4-9D74-4F5D-8A2A-66D5CE2E086BQ35054821-43B50DE7-781C-4A09-9F42-27C14936A300Q35146930-5048CD3F-25DC-4396-90BE-035EDB820D4AQ35913199-FA95E74C-8AB9-4169-8571-4A62DB3A257EQ35928728-74EEF563-541D-47EA-86CC-2D0179E4F05EQ36355467-1ECD1040-A660-4D87-A704-9BB56CE02563Q36476471-EF11052E-7DF8-4C4A-AA1C-E46E4721E3B4Q36615770-C04B7FEF-24B6-4B40-9F59-21747A130D54Q36668293-9583FF7F-1C53-44C8-AAB5-18AAFF2C9802Q36824352-B68DA816-97FA-4397-8234-ED6E54C9B5A0Q36842986-E533AA43-4FDA-42FB-B1AE-BA821D3C85C7Q37151779-03A44F8E-A7B4-47AC-8057-9ECF7423A5B4Q37169342-CA4810D1-3F72-4F28-B5EC-774968AA3353Q37207316-BBFE1907-9E1C-46F1-8B1B-0F294FD2CA09Q37230550-65896DDD-EC84-45D2-AF76-961DE96312B0Q37406772-21AE181D-93B1-4971-B02B-6CC54248A14DQ37591446-ED8E37A6-C478-40BC-8E80-D5FF647B6240Q37690351-04A365D8-E175-420B-B840-7221873E926EQ38027578-95EB9B14-B3D0-4962-9343-B68CB2C123D0Q38383042-5883EB78-2714-4FB7-A0A3-92CBF3F72F11Q38846639-7A5FAB74-CC5E-4393-B596-2A379685450BQ41495744-5F2154B6-A58D-4C7F-8C6F-E7B7EA5DB5F7Q42334186-DF127A2E-0C27-4F4A-ADC4-4DFDF040A2C5Q45153508-A524CAE1-F1FC-4466-BEB4-B6FC31B65297Q46221379-B877B06B-C411-4F10-B0D0-937115799947Q47612310-A3E5780B-2E6A-4CE8-A6B0-464D4864C760Q49951544-0685493B-73EA-41FB-B8DD-41552EC6B085Q50056115-189BFFD8-3BC4-484A-9306-BEE8CA941529Q51827185-30F23063-1DFF-4D42-AC3D-F5F58B8A8B7DQ52728983-8F9671C0-41BA-4927-A7A9-2531F4D46B47Q52868166-E227726D-87FA-4218-B52C-813B1DB5B5EAQ54384996-4197E760-AF91-4D95-9187-4B873861B2A0Q55065689-567B71CD-778C-4A26-AE03-D2F0BB8E0FCFQ58732743-39ABFBAD-96CE-4080-8BF3-66A3AA883B89
P2860
Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Risk of recurrence and chemoth ...... thologic and clinical factors.
@ast
Risk of recurrence and chemoth ...... thologic and clinical factors.
@en
type
label
Risk of recurrence and chemoth ...... thologic and clinical factors.
@ast
Risk of recurrence and chemoth ...... thologic and clinical factors.
@en
prefLabel
Risk of recurrence and chemoth ...... thologic and clinical factors.
@ast
Risk of recurrence and chemoth ...... thologic and clinical factors.
@en
P2093
P2860
P356
P1476
Risk of recurrence and chemoth ...... thologic and clinical factors.
@en
P2093
Eleftherios P Mamounas
Jack Cuzick
John F Forbes
Joseph P Costantino
Michael Crager
Norman Wolmark
Steven Shak
P2860
P304
P356
10.1200/JCO.2011.35.3714
P407
P577
2011-10-17T00:00:00Z